Safety and Immunogenicity of COVID-19 BBIBP-CorV Vaccine in Children 3–12 Years Old

Background and Objectives: In the current COVID-19 pandemic, children below the age of 12 could manifest COVID-19 symptoms and serve as a reservoir for the virus in the community. The present study was conducted to evaluate the reactogenicity, and immunogenicity of BBIBP-CorV, prior to involving thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Greish, Khaled, Alawadhi, Abdulla, Jaradat, Ahmed, Almarabheh, Amer, AlMadhi, Marwa, Jawad, Jaleela, Alsaffar, Basma, Alalawi, Ejlal, Alsayyad, Adel, Merza, Afaf, Alalawi, Batool, Qayed, Donia, Humaidan, Ahmed, Al Qahtani, Manaf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9028114/
https://www.ncbi.nlm.nih.gov/pubmed/35455335
http://dx.doi.org/10.3390/vaccines10040586

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9028114/
https://www.ncbi.nlm.nih.gov/pubmed/35455335
http://dx.doi.org/10.3390/vaccines10040586

Ejemplares similares